Pharmacology Research and Perspectives 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Adherence to newer second ‐line oral antidiabetic drugs among people with type 2 diabetes—A systematic review
The adherence to newer second-line oral antidiabetic drugs among people with type 2 diabetes was investigated in this study. A systematic literature search was performed in six databases. A total of 14948 records was retrieved from the databases of which 7 articles were included. The reported medication possession ratio (MPR) and treatment discontinuation was extracted from the articles, and these findings were visualised in figures and summarized in a narrative synthesis. The findings indicate that the adherence to the newer second-line OADs may be better than that of older OADs, but a study directly comparing older and n...
Source: Pharmacology Research and Perspectives - March 7, 2024 Category: Drugs & Pharmacology Authors: Nynne Sophie Holdt ‐Caspersen,
Claus Dethlefsen,
Peter Vestergaard,
Ole Hejlesen,
Stine Hangaard,
Morten Hasselstrøm Jensen Tags: REVIEW Source Type: research
The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses
Modelled relationship between baseline-corrected placebo-adjusted QTcF and maximum plasma mitiperstat concentration. AbstractMitiperstat is a myeloperoxidase inhibitor in clinical development for treatment of patients with heart failure and preserved or mildly reduced ejection fraction, non-alcoholic steatohepatits and chronic obstructive pulmonary disease. We aimed to assess the risk of QT-interval prolongation with mitiperstat using concentration –QT (C-QT) modeling. Healthy male volunteers were randomized to receive single oral doses of mitiperstat 5, 15, 45, 135, or 405 mg (n = 6 per dose) or matching placebo (...
Source: Pharmacology Research and Perspectives - March 6, 2024 Category: Drugs & Pharmacology Authors: Joanna Parkinson,
Jesper Sundell,
Dinko Reki ć,
Karin Nelander,
Hans Ericsson,
Ahmad Ebrahimi,
Corina Dota,
Mikael Sunnåker Tags: ORIGINAL ARTICLE Source Type: research
Identification and neuroprotective properties of NA ‐184, a calpain‐2 inhibitor
NA-184 is a novel calpain-2 inhibitor, which provides neuroprotection when administered after TBI. AbstractOur laboratory has shown that calpain-2 activation in the brain following acute injury is directly related to neuronal damage and the long-term functional consequences of the injury, while calpain-1 activation is generally neuroprotective and calpain-1 deletion exacerbates neuronal injury. We have also shown that a relatively selective calpain-2 inhibitor, referred to as C2I, enhanced long-term potentiation and learning and memory, and provided neuroprotection in the controlled cortical impact (CCI) model of traumatic...
Source: Pharmacology Research and Perspectives - March 2, 2024 Category: Drugs & Pharmacology Authors: Michel Baudry,
Yubin Wang,
Xiaoning Bi,
Yun Lyna Luo,
Zhijun Wang,
Zeechan Kamal,
Alexander Shirokov,
Ed Sullivan,
Dennis Lagasca,
Hany Khalil,
Gary Lee,
Kathy Fosnaugh,
Philippe Bey,
Shujaath Medi,
Greg Coulter Tags: ORIGINAL ARTICLE Source Type: research
Phenotype versus genotype to optimize cancer dosing in the clinical setting —focus on 5‐fluorouracil and tyrosine kinase inhibitors
AbstractCancer medicines often have narrow therapeutic windows; toxicity can be severe and sometimes fatal, but inadequate dose intensity reduces efficacy and survival. Determining the optimal dose for each patient is difficult, with body-surface area used most commonly for chemotherapy and flat dosing for tyrosine kinase inhibitors, despite accumulating evidence of a wide range of exposures in individual patients with many receiving a suboptimal dose with these strategies. Therapeutic drug monitoring (measuring the drug concentration in a biological fluid, usually plasma) (TDM) is an accepted and well validated method to ...
Source: Pharmacology Research and Perspectives - March 2, 2024 Category: Drugs & Pharmacology Authors: Jennifer H. Martin,
Peter Galettis,
Alex Flynn,
Jennifer Schneider Tags: REVIEW Source Type: research
Effects of vasoactive substances on biomechanics of small resistance arteries of male and female Dahl salt ‐sensitive rats
Possible consequences of a high salt diet on the cardiovascular system. AbstractChanges in vascular biomechanics leading to increase in arterial stiffness play a pivotal role in circulatory dysfunction. Our objectives were to examine sex-specific pharmacological changes related to the biomechanics and any structural modifications in small resistance arteries of Dahl salt-sensitive male and female rats. The composite Young modulus (CYM) was determined using pressure myograph recordings, and immunohistochemistry was used for the evaluation of any structural changes in the third-order mesenteric arteries (n = 6). Animals ...
Source: Pharmacology Research and Perspectives - March 1, 2024 Category: Drugs & Pharmacology Authors: Eric A. Mensah,
Noriko Daneshtalab,
Reza Tabrizchi Tags: ORIGINAL ARTICLE Source Type: research
Identification and neuroprotective properties of NA ‐184, a calpain‐2 inhibitor
NA-184 is a novel calpain-2 inhibitor, which provides neuroprotection when administered after TBI. AbstractOur laboratory has shown that calpain-2 activation in the brain following acute injury is directly related to neuronal damage and the long-term functional consequences of the injury, while calpain-1 activation is generally neuroprotective and calpain-1 deletion exacerbates neuronal injury. We have also shown that a relatively selective calpain-2 inhibitor, referred to as C2I, enhanced long-term potentiation and learning and memory, and provided neuroprotection in the controlled cortical impact (CCI) model of traumatic...
Source: Pharmacology Research and Perspectives - March 1, 2024 Category: Drugs & Pharmacology Authors: Michel Baudry,
Yubin Wang,
Xiaoning Bi,
Yun Lyna Luo,
Zhijun Wang,
Zeechan Kamal,
Alexander Shirokov,
Ed Sullivan,
Dennis Lagasca,
Hany Khalil,
Gary Lee,
Kathy Fosnaugh,
Philippe Bey,
Shujaath Mehdi,
Greg Coulter Tags: ORIGINAL ARTICLE Source Type: research
Effects of vasoactive substances on biomechanics of small resistance arteries of male and female Dahl salt ‐sensitive rats
Possible consequences of a high salt diet on the cardiovascular system. AbstractChanges in vascular biomechanics leading to increase in arterial stiffness play a pivotal role in circulatory dysfunction. Our objectives were to examine sex-specific pharmacological changes related to the biomechanics and any structural modifications in small resistance arteries of Dahl salt-sensitive male and female rats. The composite Young modulus (CYM) was determined using pressure myograph recordings, and immunohistochemistry was used for the evaluation of any structural changes in the third-order mesenteric arteries (n = 6). Animals ...
Source: Pharmacology Research and Perspectives - February 29, 2024 Category: Drugs & Pharmacology Authors: Eric A. Mensah,
Noriko Daneshtalab,
Reza Tabrizchi Tags: ORIGINAL ARTICLE Source Type: research
Progress in the treatment of diabetic cardiomyopathy, a systematic review
Summary of treatment methods for diabetic cardiomyopathy. AbstractDiabetic cardiomyopathy (DCM) is a condition characterized by myocardial dysfunction that occurs in individuals with diabetes, in the absence of coronary artery disease, valve disease, and other conventional cardiovascular risk factors such as hypertension and dyslipidemia. It is considered a significant and consequential complication of diabetes in the field of cardiovascular medicine. The primary pathological manifestations include myocardial hypertrophy, myocardial fibrosis, and impaired ventricular function, which can lead to widespread myocardial necros...
Source: Pharmacology Research and Perspectives - February 27, 2024 Category: Drugs & Pharmacology Authors: Yiyi Shou,
Xingyu Li,
Quan Fang,
Aqiong Xie,
Yinghong Zhang,
Xinyan Fu,
Mingwei Wang,
Wenyan Gong,
Xingwei Zhang,
Dong Yang Tags: REVIEW Source Type: research
Evaluation of the cardiac safety of parsaclisib, a selective PI3K δ inhibitor, in patients with previously treated B‐cell malignancies: Results from the CITADEL‐101 study
This study evaluated the cardiac safety of parsaclisib as monotherapy based on data from 72 patients enrolled in the CITADEL-101 study. Time-matched pharmacokinetic and ECG measurements were collected at specified times for 69 patients receiving monotherapy in doses of 5, 10, 15, 20, 3 0, and 45 mg once daily. Based on the categorical outlier analysis, no dose-dependent effect was observed on the incidence of outliers in QT interval corrected for heart rate (HR) by Fridericia's method (QTcF), HR, or cardiac conduction. Based on central tendency analysis, the least square means ( LSMs) (90% confidence interval [CI]) of Δ...
Source: Pharmacology Research and Perspectives - February 26, 2024 Category: Drugs & Pharmacology Authors: Jia Li,
Xiaohua Gong,
Xing Liu,
Xiang Liu,
Ke Szeto,
Xuejun Chen Tags: ORIGINAL ARTICLE Source Type: research
Issue Information
(Source: Pharmacology Research and Perspectives)
Source: Pharmacology Research and Perspectives - February 26, 2024 Category: Drugs & Pharmacology Tags: ISSUE INFORMATION Source Type: research
